Position in STTK
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$74,157
+$44,992 QoQ
Shares Held
11,533
-62.4% QoQ
Ownership
0.015%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2022
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in STTK Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Schonfeld Strategic Advisors LLC holds $243,253,028 across 126 Biotechnology names. STTK ranks #92 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
71,767 | $23,745,547 | |
| 2 | PTCT |
Ptc Therapeutics, Inc.
|
318,405 | $21,692,932 | |
| 3 | XENE |
Xenon Pharmaceuticals Inc.
|
324,722 | $18,882,584 | |
| 4 | INBX |
Inhibrx Biosciences, Inc.
|
254,827 | $17,132,019 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
62,142 | $11,747,945 | |
| 6 | RARE |
Ultragenyx Pharmaceutical Inc.
|
494,737 | $10,364,740 | |
| 7 | INSM |
INSMED Inc
|
56,056 | $9,166,277 | |
| 8 | ELVN |
Enliven Therapeutics, Inc.
|
218,867 | $8,579,586 |
All Filings in STTK
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $74,157 | 11,533 | Shares | Sole | 2026-05-15 | |
| 2025-03-31 | $29,165 | 30,700 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $45,254 | 37,400 | Shares | Sole | 2025-02-14 | |
| 2022-09-30 | $29,160 | 10,800 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $45,066 | 11,100 | Shares | Sole | 2022-08-15 | |
| 2022-03-31 | $80,514 | 18,900 | Shares | Sole | 2022-05-16 | |
| No filing history on record for this holder in this stock. | ||||||